AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04020185
Drug: Immuno-oncology (IO) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to product label
Trial: NCT02260947
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg
Trial: NCT02260947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01704404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02335593
Drug: Epoetin alfa 2000-4000 IU solution for injection
RxNorm normalized name: epoetin alfa 4000 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 2000-4000 IU solution for injection
Trial: NCT02335593
Drug: Iron Hydroxide Saccharate Complex Solution for injection
RxNorm normalized name: saccharated iron oxide
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron Hydroxide Saccharate Complex Solution for injection
Trial: NCT02476006
Drug: placebo (for injection training only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT02476006
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT02476006
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT00567567
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00567567
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04521556
Drug: Continuous intravenous analgesia
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Trial: NCT03286218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04407689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Trial: NCT01071655
Drug: BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly
Trial: NCT03656484
Drug: Tetracycline-Metronidazole (TM) group
RxNorm normalized name: bismuth biskalcitrate / metronidazole / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Trial: NCT03656484
Drug: TM-Melatonin-Hyaluronic acid (TM-MHa) group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Trial: NCT01348139
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled via single inhaler device (SID)
Trial: NCT01348139
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled via Turbuhaler inhaler
Trial: NCT04396223
Drug: Methotrexate 1 GM Injection
RxNorm normalized name: methotrexate 1 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate administration at 1mg/kg/day during 4 months ½ (median)
Trial: NCT02545829
Drug: HIP1302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir 292mg
Trial: NCT02545829
Drug: HGP1406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir 300mg
Trial: NCT00645268
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
Trial: NCT00874731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
Trial: NCT00458081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once per day + slightly reduced calorie diet
Trial: NCT00479882
Drug: Comparator: simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00479882
Drug: MK-0524A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
Trial: NCT00479882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00479882
Drug: MK-0524B
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00056875
Drug: recombinant human keratinocyte growth factor
RxNorm normalized name: Recombinant human keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00584584
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00584584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03583658
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: lozenges Route of administration: oromucosal
Trial: NCT02123290
Drug: DSM265 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02123290
Drug: DSM265 xmg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of DSM265 to be determined based on the results of the first cohort
Trial: NCT02123290
Drug: DSM265 ymg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of DSM265 to be determined based on the results of the second cohort
Trial: NCT03929419
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray containing placebo solution
Trial: NCT02367014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
Trial: NCT02027363
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
Trial: NCT00968825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
Trial: NCT04161729
Drug: Isotonic saline 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
Trial: NCT03882177
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, administered orally
Trial: NCT03882177
Drug: Rifafour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
Trial: NCT00376077
Drug: Methylprednisolone and IVIG
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Trial: NCT00376077
Drug: Placebo and IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Trial: NCT00245908
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00558844
Drug: Arikayce™ 560 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Trial: NCT00558844
Drug: Arikayce™ 140 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Trial: NCT00558844
Drug: Placebo for 70 mg / 140 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Trial: NCT01484600
Drug: REGN668: Injection Rate 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive REGN668 via SC injection
Trial: NCT01484600
Drug: REGN668: Injection Rate 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive study drug via alternate delivery (if necessary)
Trial: NCT01301040
Drug: epirubicin, cyclophosphamide, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
Trial: NCT03921099
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
Trial: NCT03586934
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen Tablet
Trial: NCT03586934
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib Tablet
Trial: NCT03586934
Drug: Celecoxib 400 mg
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib Tablet
Trial: NCT03586934
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac injection
Trial: NCT03586934
Drug: Acetaminophen Injectable Product
RxNorm normalized name: acetaminophen Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen injection
Trial: NCT03586934
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: meloxicam tablet
Trial: NCT03364075
Drug: Placebo Treatment
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule BID for two weeks
Trial: NCT01427725
Drug: Lipacreon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study was an observational study and no intervention was specified
Trial: NCT00504465
Drug: dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01962532
Drug: Part 1: JNJ-42756493
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
Trial: NCT00522821
Drug: intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week
Trial: NCT00522821
Drug: antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.
Trial: NCT02728921
Drug: 5% Albumin infusion 30 min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
Trial: NCT03179631
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 20 mg/kg
Trial: NCT00692055
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 375 mg
Trial: NCT00919893
Drug: Cernilton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
Trial: NCT00919893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
Trial: NCT02572336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a THR-18 lookalike, to be administered with tPA.
Trial: NCT00247624
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg every morning for 9 weeks
Trial: NCT00247624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every night for 8 weeks
Trial: NCT00562068
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00850044
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules,QD, one dose, see Arm Descriptions for more information
Trial: NCT00850044
Drug: placebo for ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, QD, one dose
Trial: NCT01343862
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
Trial: NCT00930670
Drug: Rosuvastatin-ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
Trial: NCT00147589
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01755572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Trial: NCT00672737
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
Trial: NCT01591460
Drug: ribavirin (Copegus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
Trial: NCT01591460
Drug: ribavirin (Copegus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg or 1200 mg orally once a day for 4 weeks
Trial: NCT04215393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the second stage, subjects will be receive Conbercept eys drop or a placebo.
Trial: NCT01940133
Drug: PQR309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be orally, once a day for the duration of the trial.
Trial: NCT01022112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01803282
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Trial: NCT03609892
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
Trial: NCT01810458
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Trial: NCT01810458
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Trial: NCT04407741
Drug: SHR2554+SHR1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
Trial: NCT04407741
Drug: SHR1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR1701: 30mg/kg, IV, over 30 minutes
Trial: NCT03072082
Drug: Danlou Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine \& Danlou Tablet
Trial: NCT03072082
Drug: DanLou Tablet placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine \& placebo (for Danlou Tablet)
Trial: NCT02069119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01741103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one by mouth daily for 12 weeks
Trial: NCT03014479
Drug: Daily DPP-4 inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
Trial: NCT02644278
Drug: VX-984 120 mg + PLD 40 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Trial: NCT04357002
Drug: vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Trial: NCT02489968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04357002
Drug: vaginal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Trial: NCT02618057
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO prednisolone, 1 mg/kg/day, for 5 days